Through Aprio’s relationship with one of the world’s leading strategic communications and public affairs firms, Aprio ARM has supported global immunotherapy company BioNTech with its African vaccine production initiative.
In February 2022, BioNTech unveiled plans to establish turnkey mRNA manufacturing facilities based on a container solution on the African continent, called “BioNTainer”, announced at an event attended by the presidents of Ghana, Rwanda and Senegal in Marburg, Germany.
Each BioNTainer will be equipped to manufacture a range of mRNA-based vaccines targeted to the needs of the African Union member states, and the first is expected to arrive in Africa in the second half of 2022. BioNTech expects to ship BioNTainers to Rwanda, Senegal and potentially South Africa in close coordination with the respective country.
As part of BioNTech’s media engagement for the Africa vaccine initiative, Aprio ARM developed a per country (Ghana, Rwanda, Senegal, South Africa) media engagement plans for the official announcement of this important initiative.
In the lead up to the event, Aprio ARM further deployed a robust real-time media (traditional and social) monitoring programme, providing the client with up-to-date daily media sentiment before, during and after the official event.
Client feedback on the work done: “Good to see some strong coverage of the announcement today. Thanks for your team’s work on coverage over the last week – it’s been so comprehensive!”
Aprio ARM services African markets primarily outside South Africa and has extensive working knowledge and experience across East Africa, West Africa, North Africa, Southern Africa and Indian Ocean African countries.
